Invisiderm Healthcare

Pasadena, CA

InvisiDerm was established in March 2011 and is an emerging multinational leader in proprietary circulatory health and non-invasive transdermal technologies focused on significantly improving blood flow in the body's microcirculatory system with cellular oxygenation. InvisiDerm has sales activities in over 70 countries and our safe applications are providing unparalleled health and cosmetic outcomes with zero reports of adverse side effects that are much simpler, faster, and much more affordable than any other conventional or alternative treatment on the market today. DOXYVA is InvisiDerm's first clinically proven, trademarked and patent-pending transdermal delivery system, which is the latest in the field of microcirculation applications and is named after the two main mechanisms of action related to its solution; deoxyhemoglobin vasodilator. Vasodilation in the body, triggered by DOXYVA's highly concentrated CO2 water vapor solution sprayed on the skin is the key to the drastic and unmatched long-term blood flow increase.

Several major long term trends are reshaping the healthcare industry worldwide driving the demand for InvisiDerm's proprietary, patent-pending technologies, such as the movement towards the outpatient setting, shrinking healthcare budgets, decreasing reimbursement for hospital stays, hospital outpatient centers and treatments, increasing demand for post hospitalization care and the increasing role of telemedicine and telediagnostics tracking patient progress and satisfaction. In addition, blockbuster pharmaceutical patents are expiring quickly, new medicine breakthroughs are decreasing, and profits are diminishing because of generics. The market for medical devices are driven by a high demand for minimally or non-invasive ultra-portable applications with low cost, low risk, low regulatory requirements and short time to market that require little or no reimbursement. InvisiDerm has launched the initial application of its groundbreaking new transdermal regenerative product line, DOXYVA (pronounced: Dee – OX – iva, with emphasis on the "D" and “OX”), into the consumer, sport, spa, health, beauty and wellness market in 2012 with multinational partners and suppliers.

The benefits of microcirculation is numerous as its dysfunction is increasingly being regarded by the scientific, medical, beauty, and alternative health community as the underlying cause of most chronic health complications. InvisiDerm's advanced transdermal solutions work by bolstering the body’s natural healing foundation: microcirculation. Restrictions in this form of circulation impede the flow of antibodies, white blood cells and platelets, and rob the body of oxygen. Our products are advantageous for the patient, health care practitioner, and the entire healthcare system, providing substantial cost savings and improvement in quality of life for a wide variety of health complications for people of all ages and backgrounds, both in combination with other therapies and as a standalone solution. InvisiDerm operates a state-of-the-art ISO 13485:2003 Quality Management System supply chain and is seeking medical device approvals via the U.S. FDA and in other countries for DOXYVA.